Hui-Ping Yan, Hong-Rui Lu, Yu-Xia Zhang, Liu Yang, Zhe-Ling Chen
{"title":"胃癌卵巢转移患者的手术切除和新辅助治疗:一项真实世界研究。","authors":"Hui-Ping Yan, Hong-Rui Lu, Yu-Xia Zhang, Liu Yang, Zhe-Ling Chen","doi":"10.4240/wjgs.v16.i8.2426","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Regarding when to treat gastric cancer and ovarian metastasis (GCOM) and whether to have metastatic resection surgery, there is presently debate on a global scale. The purpose of this research is to examine, in real-world patients with GCOM, the survival rates and efficacy of metastatic <i>vs</i> non-metastasized resection.</p><p><strong>Aim: </strong>To investigate the survival time and efficacy of metastatic surgery and neoadjuvant therapy in patients with GCOM.</p><p><strong>Methods: </strong>This study retrospectively analyzed the data of 41 GCOM patients admitted to Zhejiang Provincial People's Hospital from June 2009 to July 2023. The diagnosis of all patients was confirmed by pathology. The primary study endpoints included overall survival (OS), ovarian survival, OS after surgery (OSAS), disease-free survival (DFS), differences in efficacy.</p><p><strong>Results: </strong>This study had 41 patients in total. The surgical group (<i>n</i> = 27) exhibited significantly longer median OS (mOS) and median overall months (mOM) compared to the nonoperative group (<i>n</i> = 14) (mOS: 23.0 <i>vs</i> 6.9 months, <i>P</i> = 0.015; mOM: 18.3 <i>vs</i> 3.8 months, <i>P</i> = 0.001). However, there were no significant differences observed in mOS, mOM, median OSAS (mOSAS), and median DFS (mDFS) between patients in the surgical resection plus neoadjuvant therapy group (<i>n</i> = 11) and those who surgical resection without neoadjuvant therapy group (<i>n</i> = 16) (mOS: 26.1 months <i>vs</i> 21.8 months, <i>P</i> = 0.189; mOM: 19.8 <i>vs</i> 15.2 months, <i>P</i> = 0.424; mOSAS: 13.9 <i>vs</i> 8.7 months, <i>P</i> = 0.661, mDFS: 5.1 <i>vs</i> 8.2 months, <i>P</i> = 0.589).</p><p><strong>Conclusion: </strong>Compared to the non-surgical group, the surgical group's survival duration and efficacy are noticeably longer. The efficacy and survival time of the direct surgery group and the neoadjuvant therapy group did not differ significantly.</p>","PeriodicalId":23759,"journal":{"name":"World Journal of Gastrointestinal Surgery","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11362938/pdf/","citationCount":"0","resultStr":"{\"title\":\"Surgical resection and neoadjuvant therapy in patients with gastric cancer and ovarian metastasis: A real-world study.\",\"authors\":\"Hui-Ping Yan, Hong-Rui Lu, Yu-Xia Zhang, Liu Yang, Zhe-Ling Chen\",\"doi\":\"10.4240/wjgs.v16.i8.2426\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Regarding when to treat gastric cancer and ovarian metastasis (GCOM) and whether to have metastatic resection surgery, there is presently debate on a global scale. The purpose of this research is to examine, in real-world patients with GCOM, the survival rates and efficacy of metastatic <i>vs</i> non-metastasized resection.</p><p><strong>Aim: </strong>To investigate the survival time and efficacy of metastatic surgery and neoadjuvant therapy in patients with GCOM.</p><p><strong>Methods: </strong>This study retrospectively analyzed the data of 41 GCOM patients admitted to Zhejiang Provincial People's Hospital from June 2009 to July 2023. The diagnosis of all patients was confirmed by pathology. The primary study endpoints included overall survival (OS), ovarian survival, OS after surgery (OSAS), disease-free survival (DFS), differences in efficacy.</p><p><strong>Results: </strong>This study had 41 patients in total. The surgical group (<i>n</i> = 27) exhibited significantly longer median OS (mOS) and median overall months (mOM) compared to the nonoperative group (<i>n</i> = 14) (mOS: 23.0 <i>vs</i> 6.9 months, <i>P</i> = 0.015; mOM: 18.3 <i>vs</i> 3.8 months, <i>P</i> = 0.001). However, there were no significant differences observed in mOS, mOM, median OSAS (mOSAS), and median DFS (mDFS) between patients in the surgical resection plus neoadjuvant therapy group (<i>n</i> = 11) and those who surgical resection without neoadjuvant therapy group (<i>n</i> = 16) (mOS: 26.1 months <i>vs</i> 21.8 months, <i>P</i> = 0.189; mOM: 19.8 <i>vs</i> 15.2 months, <i>P</i> = 0.424; mOSAS: 13.9 <i>vs</i> 8.7 months, <i>P</i> = 0.661, mDFS: 5.1 <i>vs</i> 8.2 months, <i>P</i> = 0.589).</p><p><strong>Conclusion: </strong>Compared to the non-surgical group, the surgical group's survival duration and efficacy are noticeably longer. The efficacy and survival time of the direct surgery group and the neoadjuvant therapy group did not differ significantly.</p>\",\"PeriodicalId\":23759,\"journal\":{\"name\":\"World Journal of Gastrointestinal Surgery\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2024-08-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11362938/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World Journal of Gastrointestinal Surgery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4240/wjgs.v16.i8.2426\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Gastrointestinal Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4240/wjgs.v16.i8.2426","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:关于何时治疗胃癌和卵巢转移(GCOM)以及是否进行转移切除手术,目前在全球范围内存在争议。本研究的目的是在现实世界的胃癌和卵巢癌转移患者中,研究转移性切除手术与非转移性切除手术的生存率和疗效:本研究回顾性分析了 2009 年 6 月至 2023 年 7 月期间浙江省人民医院收治的 41 例 GCOM 患者的数据。所有患者均经病理确诊。主要研究终点包括总生存期(OS)、卵巢生存期、术后OS(OSAS)、无病生存期(DFS)、疗效差异:本研究共有 41 名患者。手术组(n = 27)的中位手术生存期(mOS)和中位总月数(mOM)明显长于非手术组(n = 14)(mOS:23.0 个月 vs 6.9 个月,P = 0.015;mOM:18.3 个月 vs 3.8 个月,P = 0.001)。然而,手术切除加新辅助治疗组(n = 11)与手术切除不加新辅助治疗组(n = 16)的患者在 mOS、mOM、中位 OSAS(mOSAS)和中位 DFS(mDFS)方面没有观察到明显差异(mOS:26.1 个月 vs 21.8 个月,P = 0.015;mOM:18.3 个月 vs 3.8 个月,P = 0.001)。1个月 vs 21.8个月,P=0.189;mOM:19.8个月 vs 15.2个月,P=0.424;mOSAS:13.9个月 vs 8.7个月,P=0.661;mDFS:5.1个月 vs 8.2个月,P=0.589):结论:与非手术组相比,手术组的存活时间和疗效明显更长。结论:与非手术组相比,手术组的生存时间和疗效明显更长,而直接手术组和新辅助治疗组的疗效和生存时间差异不大。
Surgical resection and neoadjuvant therapy in patients with gastric cancer and ovarian metastasis: A real-world study.
Background: Regarding when to treat gastric cancer and ovarian metastasis (GCOM) and whether to have metastatic resection surgery, there is presently debate on a global scale. The purpose of this research is to examine, in real-world patients with GCOM, the survival rates and efficacy of metastatic vs non-metastasized resection.
Aim: To investigate the survival time and efficacy of metastatic surgery and neoadjuvant therapy in patients with GCOM.
Methods: This study retrospectively analyzed the data of 41 GCOM patients admitted to Zhejiang Provincial People's Hospital from June 2009 to July 2023. The diagnosis of all patients was confirmed by pathology. The primary study endpoints included overall survival (OS), ovarian survival, OS after surgery (OSAS), disease-free survival (DFS), differences in efficacy.
Results: This study had 41 patients in total. The surgical group (n = 27) exhibited significantly longer median OS (mOS) and median overall months (mOM) compared to the nonoperative group (n = 14) (mOS: 23.0 vs 6.9 months, P = 0.015; mOM: 18.3 vs 3.8 months, P = 0.001). However, there were no significant differences observed in mOS, mOM, median OSAS (mOSAS), and median DFS (mDFS) between patients in the surgical resection plus neoadjuvant therapy group (n = 11) and those who surgical resection without neoadjuvant therapy group (n = 16) (mOS: 26.1 months vs 21.8 months, P = 0.189; mOM: 19.8 vs 15.2 months, P = 0.424; mOSAS: 13.9 vs 8.7 months, P = 0.661, mDFS: 5.1 vs 8.2 months, P = 0.589).
Conclusion: Compared to the non-surgical group, the surgical group's survival duration and efficacy are noticeably longer. The efficacy and survival time of the direct surgery group and the neoadjuvant therapy group did not differ significantly.